ProShare Advisors’s Beta Bionics BBNX Stock Holding History

ProShare Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,115	Closed	-$217K	–	2057
2025 Q4	$217K	Buy	+7,115	New	+$190K	﹤0.01%	1666

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ProShare Advisors's BBNX Position: Q1 2026 in Review

ProShare Advisors sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 7,115 shares — an estimated $217K sold.

ProShare Advisors first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $217K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

ProShare Advisors reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 7,115 Beta Bionics shares in Q1 2026, an estimated $217K.
ProShare Advisors first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
ProShare Advisors's Beta Bionics position peaked at $217K in Q4 2025.
130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.